Welcome to our dedicated page for Maxcyte news (Ticker: MXCT), a resource for investors and traders seeking the latest updates and insights on Maxcyte stock.
MaxCyte, Inc. (NASDAQ: MXCT) is a cell-engineering focused company whose news flow centers on its enabling platform technologies, financial performance and strategic partnerships in next-generation cell-based therapeutics. As a commercial cell engineering company, MaxCyte regularly issues updates on its core business revenue, Strategic Platform License (SPL) program-related revenue and total cash, cash equivalents and investments, giving investors insight into how its platform is being adopted and how its financial profile is evolving.
News about MaxCyte often includes quarterly and annual financial results, preliminary earnings updates and revised guidance ranges for core revenue and SPL program-related revenue. These releases typically discuss core revenue from instruments, processing assemblies and consumables, licenses, assay services and other categories, as well as program-related revenue tied to SPL milestones and royalties. Management commentary in these announcements frequently addresses operating environment conditions, cost structure, operational restructuring and the company’s path toward profitability.
Another key category of MXCT news involves new and expanded SPL agreements with biotechnology partners. Recent press releases have highlighted SPLs with companies such as Adicet Bio and Moonlight Bio, where MaxCyte’s Flow Electroporation technology and ExPERT platform are being deployed to support scalable development and manufacturing of gene-edited T cell therapies and gamma delta T cell programs. These partnership updates help illustrate how MaxCyte’s platform is used across different cell therapy pipelines.
Corporate developments also feature in the company’s news stream. Examples include the announcement of an operational restructuring and workforce reduction plan designed to reduce costs and align resources with strategic priorities, as well as leadership transitions such as planned changes in the chief financial officer role. For investors and industry observers, following MXCT news can provide ongoing context on MaxCyte’s business performance, partner activity and strategic decisions within the cell and gene therapy ecosystem.
MaxCyte (NASDAQ:MXCT) has signed a Strategic Platform License Agreement with Anocca AB for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The agreement grants Anocca non-exclusive research, clinical, and commercial rights to support their TCR-T cell therapy development.
Under the agreement, MaxCyte will receive annual licensing fees and program-related revenue. The partnership aims to enhance Anocca's cell therapy manufacturing capabilities, particularly for their lead program targeting KRAS-driven advanced pancreatic cancer currently in clinical development. Anocca recently received GMP compliance certification and manufacturing license from Swedish regulators.
MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its second quarter 2025 financial results announcement for August 6, 2025, after the U.S. market close.
The company will host a conference call at 4:30 p.m. Eastern Time to discuss the results. Investors must register online to participate, preferably a day in advance. A live and archived webcast will be available in the "Events" section of MaxCyte's investor relations website.
MaxCyte (NASDAQ: MXCT), a cell-engineering platform technology company, has scheduled its first quarter 2025 financial results announcement for May 7th, 2025, after the U.S. market close. The company will host a conference call with management at 4:30 p.m. Eastern Time to discuss the quarterly performance.
Investors interested in participating in the earnings call must register online, preferably at least one day in advance. A live webcast and recording of the event will be accessible through the 'Events' section on MaxCyte's investor relations website.
MaxCyte (NASDAQ: MXCT) reported Q4 and full year 2024 financial results, showing mixed performance. Q4 total revenue decreased 45% to $8.7M compared to Q4 2023, primarily due to one-time approval milestones in the previous year. However, core business revenue grew 20% to $8.6M in Q4 2024.
For the full year 2024, total revenue decreased 6% to $38.6M, while core business revenue increased 9% to $32.5M. The company maintained strong liquidity with $190.3M in cash and investments. MaxCyte expanded its Strategic Platform License (SPL) portfolio to 28 active agreements, including 18 clinical programs and 1 commercial program.
Looking ahead, MaxCyte provided 2025 guidance projecting core revenue growth of 8-15% and expecting approximately $5M in SPL Program-related revenue. The company anticipates ending 2025 with $160M in total cash and investments.
MaxCyte (MXCT) has entered into a strategic platform license agreement with TG Therapeutics for the use of MaxCyte's Flow Electroporation® technology and ExPERT™ platform. The partnership aims to support the development and commercialization of azer-cel, TG's allogeneic CD19 CAR T cell therapy program for autoimmune diseases.
Under the agreement, TG Therapeutics receives non-exclusive research, clinical and commercial rights, while MaxCyte will receive annual licensing fees and program-related revenue. TG Therapeutics recently acquired worldwide license to azer-cel from Precision BioSciences and has received FDA clearance for an IND application in progressive forms of multiple sclerosis (MS), with Phase 1 trials targeted for 2025.
MaxCyte (NASDAQ: MXCT; LSE: MXCT), a cell-engineering platform technology company, has announced it will release its fourth quarter and full year 2024 financial results after U.S. market close on March 11th, 2025. The company will host a conference call with management to discuss the results at 4:30 p.m. Eastern Time on the same day.
Additionally, MaxCyte management will participate in the 45th Annual TD Cowen Healthcare Conference, delivering a fireside chat on March 3rd at 10:30 a.m. ET. Both events will be accessible via webcast through the company's investor relations website.
MaxCyte (MXCT) has acquired SeQure Dx, a leader in on-target and off-target editing assessment services for cell and gene therapies, for an initial $4.5 million in cash with potential additional contingent payments up to $2.5 million based on revenue targets.
SeQure Dx, headquartered in Waltham, Massachusetts, specializes in assays for editing confirmation and risk assessment across viral and non-viral gene editing modalities. The acquisition aims to strengthen MaxCyte's position in serving cell and gene therapy developers with tools spanning R&D through commercialization.
SeQure Dx generated approximately $1.7 million in revenue and incurred a $6.5 million loss in 2024 (based on unaudited results through November). The company transitioned from an assay development and licensing organization to a contract service provider in March 2024. MaxCyte expects improved financial performance through service revenue activity, cost synergies, and operational efficiencies.
MaxCyte (NASDAQ: MXCT) has released preliminary unaudited financial results for Q4 and full year 2024. The company expects Q4 core revenue between $8.3-8.5 million, up from $7.2 million in Q4 2023. Full-year core revenue is anticipated at $32.2-32.4 million, showing 8-9% growth compared to $29.8 million in 2023.
The company's cash position as of December 31, 2024, is expected to be approximately $190 million, exceeding both initial guidance of $175 million and updated December guidance of $185 million, though down from $211 million at the end of 2023.
In 2024, MaxCyte added six new SPL customers and supported the commercial launch of the first FDA-approved non-viral gene edited cell therapy product. Complete SPL program-related revenue and total revenue figures for Q4 and full year 2024 will be reported in March 2025.
FAQ
What is the current stock price of Maxcyte (MXCT)?
What is the market cap of Maxcyte (MXCT)?
